Chemical formula: C₂₈H₂₈F₂N₆O₃ Molecular mass: 534.568 g/mol PubChem compound: 51049968
Rimegepant selectively binds with high affinity to the human calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. The relationship between pharmacodynamic activity and the mechanism(s) by which rimegepant exerts its clinical effects is unknown.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CD06 | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VYDURA Oral lyophilisate | European Medicines Agency (EU) | MPI, EU: SmPC | |
| NURTEC ODT Orally disintegrating tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Rimegepant is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Estonia (EE)
France (FR)
Israel (IL)
Italy (IT)
Lithuania (LT)
Romania (RO)
Spain (ES)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
